<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04003818</url>
  </required_header>
  <id_info>
    <org_study_id>LPS16229</org_study_id>
    <secondary_id>U1111-1230-0601</secondary_id>
    <nct_id>NCT04003818</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Teicoplanin in CDAD</brief_title>
  <official_title>Prospective, Interventional, Phase IV Study, Evaluating the Efficacy and Safety of Teicoplanin (100-200 mg, Administered Orally Twice a Day) in Patients With Clostridium Difficile Infection-associated Diarrhea and Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      Explore the efficacy of teicoplanin (100-200 mg administered orally twice a day for 7 to 14
      days) in patients with Clostridium difficile infection-associated diarrhea and colitis

      Secondary Objective:

      Evaluate the safety of teicoplanin in patients with Clostridium difficile
      infection-associated diarrhea and colitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximate 10 weeks
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure rate</measure>
    <time_frame>2 days after 7-14 days treatment</time_frame>
    <description>Clinical cure is defined as: Resolution of diarrhea (ROD) (≤ 3 unformed bowel movement (UBM) per day for at least 2 consecutive days) on study treatment and maintained for 2 days after End of treatment (EOT), AND No additional antimicrobial treatment active against Clostridium difficile-associated diarrhea (CDAD) or fecal microbiota transplant (FMT) between first dose of study drug and 2 days after EOT (inclusive)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>Recurrence is defined as reappearance of diarrhea during the 8-week follow-up period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to resolution of diarrhea</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>Resolution of diarrhea (ROD) (≤ 3 unformed bowel movement (UBM) per day for at least 2 consecutive days) on study treatment and maintained for 2 days after end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of nephrotoxicity</measure>
    <time_frame>Until 10 weeks</time_frame>
    <description>Nephrotoxicity is defined as: serum creatinine increase of more than 0.5 mg/dL if the baseline serum creatinine was ≤ 3 mg/dL or a rise of &gt; 1 mg/dL if the initial serum creatinine was &gt; 3 mg/dL; or 50% increase from baseline; or a drop in calculated creatinine clearance using Cockroft-Gault formula of ≥ 50% from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hepatotoxicit</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>Hepatotoxicity is defined as: AST or ALT 3 times upper limit of normal or if AST or ALT baseline is abnormal, AST or ALT increase of ≥ 3 times the baseline and adverse events/ reactions using the MedDRA SMQ (Standardised MedDRA Query) &quot;Hepatic Disorders&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thrombocytopenia</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>Thrombocytopenia is defined as: platelets &lt; 100 000/mm3 or &lt; 100 Giga/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hearing and balance/vestibular disorders</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>Hearing and balance/vestibular disorders are defined as: identified via PT terms using MedDRA SMQ for &quot;hearing and vestibular disorders&quot; (narrow) and additionally the PT &quot;balance disorder&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional renal endpoints: renal failure, dialysis and renal replacement therapy</measure>
    <time_frame>Until 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any untoward adverse events/reactions</measure>
    <time_frame>Up to 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Clostridium Difficile Infection-associated Diarrhea and Colitis</condition>
  <arm_group>
    <arm_group_label>Teicoplanin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>teicoplanin, administered orally 100-200 mg, twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEICOPLANIN</intervention_name>
    <description>Pharmaceutical form:solution for oral administration Route of administration: oral</description>
    <arm_group_label>Teicoplanin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Signed Informed Consent.

          -  Male or female no less than 18 years of age.

          -  Inpatient with a diagnosis of mild-moderate or severe CDAD (first occurrence or first
             recurrence within 3 months) with: Diarrhea: a change in bowel habits with &gt; 3 liquid
             or unformed bowel movements (UBM) within 24 hours prior to enrollment, AND Positive C.
             difficile toxin test on a stool sample produced within 72 hours prior to enrollment.

        Exclusion criteria:

          -  More than one previous episode of CDAD in the 3-month period prior to enrollment.

          -  Evidence of life-threatening or fulminant CDAD.

          -  Likelihood of death within 72 hours from any cause.

          -  History of inflammatory colitides, chronic abdominal pain, or chronic diarrhea

          -  Antimicrobial treatment active against CDAD administered for &gt; 24 hours except for
             metronidazole treatment failures (MTF).

          -  Known hypersensitivity or contraindication to teicoplanin.

          -  Pregnant or nursing females.

          -  Unable or unwilling to comply with all protocol requirements.

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>investigational site CHINA</name>
      <address>
        <city>China</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teicoplanin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

